SG Americas Securities’s Terns Pharmaceuticals TERN Stock Holding History

SG Americas Securities’s Portfolio TERN Stock Details TERN Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q2	–	Sell	-22,774	Closed	-$1.2M	–	3663
2026 Q1	$1.2M	Sell	22,774 -21,083	-48%	-$866K	﹤0.01%	1643
2025 Q4	$1.77M	Buy	+43,857	New	+$1.01M	﹤0.01%	1604
2025 Q2	–	Sell	-413,822	Closed	-$1.14M	–	3579
2025 Q1	$1.14M	Buy	413,822 +380,489	+1,141%	+$1.55M	﹤0.01%	1078
2024 Q4	$185K	Buy	33,333 +9,523	+40%	+$64.5K	﹤0.01%	2230
2024 Q3	$199K	Buy	+23,810	New	+$196K	﹤0.01%	2500

Other funds holding TERN

IFP Advisors Tampa, Florida $5.54B AUM 27.43% 1-Year Est. Return

SG Americas Securities's TERN Position: Q2 2026 in Review

SG Americas Securities sold out of Terns Pharmaceuticals (TERN) in Q2 2026, closing a stake of 22,774 shares — an estimated $1.2M sold.

SG Americas Securities first reported a position in TERN in Q3 2024 and held it in 5 quarters. The position peaked at $1.77M in Q4 2025. 1 fund tracked by Wall St. Rank holds TERN as of Q2 2026.

SG Americas Securities reported no remaining Terns Pharmaceuticals position as of Q2 2026 after selling out during the quarter.
SG Americas Securities sold 22,774 Terns Pharmaceuticals shares in Q2 2026, an estimated $1.2M.
SG Americas Securities first reported a position in Terns Pharmaceuticals in Q3 2024 and held it in 5 quarters.
SG Americas Securities's Terns Pharmaceuticals position peaked at $1.77M in Q4 2025.
1 fund tracked by Wall St. Rank held Terns Pharmaceuticals as of Q2 2026.

Based on SG Americas Securities's 13F filing for Q2 2026, filed 7 Aug 2026.